Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
About this item
Full title
Author / Creator
Publisher
Japan: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Japan: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
It is strongly suggested that dipeptidyl peptidase‐4 inhibitors are associated with increased risk of bullous pemphigoid onset, especially in the elderly. Heightened clinical vigilance for bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor use is required in daily diabetes care.
Alternative Titles
Full title
Bullous pemphigoid with dipeptidyl peptidase‐4 inhibitors: Clinical features and pathophysiology
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_ca12482108d34b4f91a5057483822e5c
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ca12482108d34b4f91a5057483822e5c
Other Identifiers
ISSN
2040-1116
E-ISSN
2040-1124
DOI
10.1111/jdi.13060
